How Much Does Zepbound Cost Without Insurance in 2026?

Zepbound is tirzepatide, a once-weekly injectable medication FDA-approved in November 2023 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition. In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, making it the first drug approved for that indication. Mounjaro is the same molecule sold under a different brand name and label for type 2 diabetes.

The retail list price is approximately $1,059 per month for Zepbound prefilled pens. Self-pay options through LillyDirect cost significantly less: $299 per month for 2.5 mg or 5 mg vials, and $449 per month for higher maintenance doses (7.5 mg through 15 mg). Eli Lilly reduced the high-dose vial price from $549 to $449 in December 2025. For semaglutide-based alternatives, compare Wegovy without insurance. GoodRx coupons at retail pharmacies typically bring the price to $950 to $1,050 per month, which is still far above LillyDirect. Commercially insured patients who use the Lilly Savings Card can access Zepbound for $0 per month; that card cannot be used with Medicare, Medicaid, or other government plans.

No FDA-approved generic for tirzepatide exists as of 2026, and none is expected before January 2036 at the earliest. Eli Lilly holds patents on the molecule, the formulation, and the autoinjector device, with some protections extending to around 2041. Compounded tirzepatide from 503B pharmacies was widely available during the drug shortage period of 2023 and 2024. The FDA moved to restrict compounding following the shortage resolution, and legal access to compounded tirzepatide is limited as of mid-2026. The LillyDirect vial program is the primary low-cost option for patients without insurance or with high deductibles. Patients should also review whether Medicare covers GLP-1 weight loss drugs before ruling out coverage. The same molecule marketed as Mounjaro for diabetes may be covered under different plan rules.

What Zepbound Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same zepbound can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Zepbound is a self-administered drug billed through the pharmacy benefit, not through hospital drug administration billing. This means traditional inpatient hospital charges for Zepbound are uncommon. However, if you receive tirzepatide during a supervised weight management program or inpatient setting, the hospital may bill the drug at their facility acquisition rate, typically marked up 50 to 150 percent above the wholesale acquisition cost. On a drug with a list price near $1,059 per month, that produces a facility charge of approximately $1,589 to $2,648 for a single month's supply.

The more common cost problem with Zepbound is not a hospital bill but a pharmacy bill: the list-price amount can appear on a claim if the pharmacy does not apply the savings card, if the prior authorization is delayed, or if the drug lands on a non-preferred specialty tier. Patients who receive an unexpected pharmacy bill above $449 should compare the LillyDirect self-pay vial cost before appealing the tier placement or prior authorization denial. In many cases, LillyDirect is cheaper than the patient's cost share through insurance.

The structural price gap between the retail list price and the $299 LillyDirect self-pay price reflects how pharmaceutical pricing in the U.S. works. Manufacturers set a high list price for insurance negotiation while offering parallel direct-pay channels. The gap is a discount Eli Lilly extends to self-pay patients to maintain market access. Never pay the retail list price for Zepbound if you are uninsured: LillyDirect is the first call to make.

Patient Assistance Programs

Eli Lilly's standard Lilly Cares patient assistance program does not include Zepbound as of 2026. The table below shows all available cost-reduction pathways, including Lilly-run programs, government programs, and third-party foundations, with eligibility criteria:

Medicare Part D

Medicare Part D coverage for Zepbound depends on the indication. For moderate-to-severe obstructive sleep apnea in adults with obesity, Zepbound became coverable under standard Medicare Part D following the FDA's December 2024 approval. Whether a specific plan covers it and at what tier requires checking your plan's formulary directly. Prior authorization is typically required, and the prescribing physician must document the OSA diagnosis. If your plan covers Zepbound for OSA, the 2026 Part D annual out-of-pocket cap of $2,100 applies.

For weight loss, traditional Medicare Part D did not cover Zepbound because the Social Security Act historically barred Medicare from covering drugs prescribed solely for weight loss. The CMS Medicare GLP-1 Bridge demonstration changes that temporarily. This program runs from July 1, 2026 through December 31, 2027 and provides eligible Part D beneficiaries access to Zepbound (KwikPen) at $50 per month. Eligibility for the Bridge requires enrollment in a participating standalone Part D plan (PDP) or Medicare Advantage plan with drug coverage (MA-PD) and a qualifying cardiovascular comorbidity: prior myocardial infarction, stroke, or peripheral arterial disease at BMI 27 or higher; or heart failure with preserved ejection fraction (HFpEF), uncontrolled hypertension, or chronic kidney disease stage 3a or higher at BMI 30 or higher. Simple obesity without a cardiovascular comorbidity does not qualify for the Bridge.

The $50 copayment under the GLP-1 Bridge does not count toward the 2026 Part D annual out-of-pocket cap of $2,100. Beneficiaries already receiving Zepbound under a standard Part D plan for a covered indication such as OSA are not eligible for the GLP-1 Bridge separately; they continue under their plan's standard benefit. The GLP-1 Bridge expires December 31, 2027 with no current plan for extension. Zepbound's two FDA-approved indications are chronic weight management (obesity and overweight with a weight-related condition) and moderate-to-severe obstructive sleep apnea in adults with obesity. There is no FDA-approved cardiovascular indication for Zepbound; that approval belongs to Wegovy (semaglutide).

Common Zepbound Billing Errors

Zepbound billing errors typically occur at the pharmacy benefit level rather than on a hospital bill. Check for these issues if you receive an unexpected charge:

• Savings card not applied: pharmacies sometimes fail to run the Lilly Savings Card. The card is applied electronically using BIN/PCN numbers from the card. If billed at list price with commercial insurance, ask the pharmacist to reprocess with the savings card before paying anything.
• Billed at non-preferred specialty tier: many insurance formularies place Zepbound on a high-cost specialty tier. If your plan covers tirzepatide for diabetes under Mounjaro, check whether a formulary exception or step therapy override applies to Zepbound for your indication.
• Prior authorization denial coded as weight loss when OSA is the indication: plans may deny Zepbound as a weight-loss drug even when prescribed for obstructive sleep apnea. Zepbound's two FDA-approved indications are chronic weight management and moderate-to-severe OSA (approved December 2024). If denied, confirm whether your physician documented the OSA diagnosis (ICD-10: G47.33), then appeal with clinical documentation including sleep study results.
• Mounjaro vs. Zepbound formulary confusion: Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity and OSA) are the same molecule but carry different NDC numbers and different formulary positions. A plan that covers Mounjaro may not automatically cover Zepbound. Pharmacy billing errors can arise when a pharmacist substitutes one NDC for the other.
• LillyDirect not used when cheaper: patients without insurance or with high deductibles often overpay at retail pharmacies. LillyDirect self-pay vials at $299 per month (2.5 mg or 5 mg) or $449 per month (7.5 mg through 15 mg) are frequently cheaper than the patient cost-share through a commercial plan with a high deductible. Compare both options before filling a prescription.

Frequently Asked Questions